**Charity Registration No. 285946**
**Company Registration No. 493724 (England and Wales)**
**THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025**
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **LEGAL AND ADMINISTRATIVE INFORMATION**
## **Trustees**
Dr Zaloa Agirre-Arrizubieta Professor Mark Baker Dr Natalie Ross Dr Charles Fry Dr Sushma Goyal Dr Brython (Appointed 4 October 2024) Hywel Dr Samantha Jefferson Dr Andrew Michell Dr Friederike Moeller Dr Giulia Navarro Dr Gareth Payne Dr Ronit Pressler Dr Syed Shah Dr Rachel (Appointed 4 October 2024) Thornton Dr Simon Freilich Dr Jiten Mistry Dr Tatyana Yermakova Dr Stephan (Appointed 4 October 2024) Jaiser Professor Martin Koltzenburg (Resigned 4 October 2024) (Resigned 4 October 2024)
|**Charity number**|285946|
|---|---|
|**Company number**|493724|
|**Registered office**|9 Bonhill Street|
||London EC2A|
||4DJ|
|**Independent examiner**|Katherine Dee FCA ACA|
||Begbies Chartered Accountants|
||9 Bonhill Street London|
EC2A 4DJ
**THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **CONTENTS**
**Page** President's statement 1 Trustees' report 2 - 4 Independent examiner's report 5 Statement of financial activities 6 - 7 Summary income and expenditure account 8 Balance sheet 9 Notes to the financial statements 10 - 19
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **PRESIDENT'S STATEMENT**
## _**FOR THE YEAR ENDED 30 JUNE 2025**_
The BSCN has been active this year promoting the specialty and scientific knowledge through two Scientific meetings, including a joint meeting held with the Irish Society of Clinical Neurophysiology at the Radisson Blu St Helen’s Hotel, Stillorgan, Dublin, and three training days for the Specialist Trainees across the UK. The Society also continues to promote and support UK Clinical Neurophysiology in other areas; for example, we continue to award an essay prize for medical students to encourage interest in, and consideration of the specialty, and this year we have received a record number of applicants.
The Society’s members have also been meeting with NHS England (the Department of Health) and NHS Wales to discuss issues relating to the profession and to lobby for funding for more training posts in our specialty to meet the needs of patients across the UK. The Society continues to award bursaries to UK trainees to help cover training course fees and associated travel costs, and in the 2024-2025 financial year the society has been particularly generous.
Finally, I look forward to interacting with those of our international colleagues (some of whom are also members of the BSCN) attending the European Congress of Clinical Neurophysiology, which will be hosted this year in London.
..............................
## **Dr Gareth Payne President**
5th October 2025 Date: .........................
- 1 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
The trustees of The British Society for Clinical Neurophysiology (BSCN) present their report and accounts for the year ended 30 June 2025 and confirm that they comply with current statutory requirements and with the requirements of the Society's governing instrument.
The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable company's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".
## **Objectives and activities**
The charitable company's objects are to promote and assist the science and practice of electroencephalography, clinical neurophysiology and allied subjects.
The policies adopted in furtherance of these objects are as following and there has been no change in these during the year:
1. To organise scientific meetings of the Society (usually 2-3 per year)
2. To organise teaching courses (triennial)
3. To organise essay prizes in the subject
4. To provide an Annual Medical Student Bursary, of up to £5,000, in support of a Neurosciences BSc.
The trustees consider that they have complied with the duty of section 17(5) of the Charities Act 2011, having paid due regard to public benefit guidance issued by the Charity Commission in deciding what activities the charitable company should undertake.
## **Achievements and performance**
The BSCN has been involved in presenting the usual two Scientific meetings in Autumn and Spring, with the Spring meeting being held jointly with the Irish Society of Clinical Neurophysiology. Three training days ere also held for the Specialist Trainees across the UK.
The BSCN continues to honour achievement in clinical neurophysiology, and award prizes and grants. The total cost of awards for the 2024/5 year was £1,500.
The Medical Student Essay Prize of £500 which was awarded to Thanusa Thatparan of the University of Sheffield.
The Adrian Prize of £1,000 was awarded to Dr Charles Fry.
Book bursaries totalling £159 were awarded to one recipient.
General bursaries totalling £3,188 were awarded to eight people of which £2,688 were ISCN 2025 bursaries.
## Subscriptions
Income from membership subscriptions increased by 16.9% during the year to 30th June 2025, however as income is recognised on receipt, the difference is largely due to payment timings at the year end.
## Meetings
Expenses relating to Society meetings amounted to £10,656, and income amounted to £47,135. The cost of events decreased significantly due to the joint Spring scientific meeting.
These costs are directly attributable to the meetings, and are before the share of governance or support costs.
## Professional fees
Independent Examination for the year were £3,133.
- 2 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
## Investments
The market value of the Society's investments increased during the year by £2,075 (2.3%). These investments produced dividends and gross interest of £4,863.
## **Financial review**
The Society's financial position remains very sound. This year the Society reports a net surplus for the year of £45,383; however, the Society always aims to leave sufficient funds in order to fund the running of large events, including future triennial teaching courses in Oxford. After the success of the Society’s bid to host the ECCN in 2025, we have been working on the ECCN 2025 budget with a professional conference organiser (PCO), who have set up a limited company, with Dr Nick Kane and Dr Jacquie Deeb as Directors. This will ensure that the Society does not have any financial liability for ECCN 2025 and will not be expected to underwrite the congress. However, given the ECCN will take place instead of the triennial course in 2025, the Society will provide support for the ECCN, as it has previously for the triennial course. The ECCN company is not considered to be a related party to the Society and their activities are not incorporated into these accounts.
## Reserves policy
The Society holds reserves sufficient to underwrite any potential losses in respect of the next triennial teaching course. At the year end the reserves stood at £62,672, of which £10,000 is held as an expendable endowment for the Dr last Memorial fund and £23,086 are restricted funds. The remaining £229,586 unrestricted funds are freely available to support the charitable objects.
## Investments policy
The Society's investments are held in charity-specific low risk unit trusts and fixed interest securities.
## Risk Mitigation
The trustees have reviewed the Society's exposure to major risks and have accordingly established that the Society's reserves are sufficient to mitigate them.
## **Structure, governance and management**
The charitable company is a company limited by guarantee, and is incorporated in England. The company's registered address is 9 Bonhill Street, London, EC2A 4DJ.
The governing instrument is the Memorandum and Articles of Association (updated October 2021). The society is governed by a council of management, which consists of the Officers of the Society, the Chairmen of the Medical and Clinical Scientists Standing Committees, not more than eight ordinary members of the Council (being corporate members of the Society), and such corporate members of the Society (not exceeding three) as may be co-opted by Council at its discretion.
Trustees (Officers of the Society) are appointed in accordance with the Memorandum and Articles of Association. Persons are nominated for election as officers of the Society at least 6 weeks prior to the Annual General Meeting. If more than one person is nominated, a vote is taken at the AGM, otherwise the election is agreed by the council.
Newly appointed Officers are either already experienced in the role, or share duties and shadow the outgoing Officer.
The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:
Dr Zaloa Agirre-Arrizubieta Professor Mark Baker Dr Natalie Ross Dr Charles Fry (Appointed 4 October 2024) Dr Sushma Goyal Dr Brython Hywel Dr Stephan Jaiser (Resigned 4 October 2024) Dr Samantha Jefferson
- 3 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **TRUSTEES' REPORT (CONTINUED)(INCLUDING DIRECTORS' REPORT)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
Professor Martin Koltzenburg (Resigned 4 October 2024) Dr Andrew Michell Dr Friederike Moeller Dr Giulia Navarro (Appointed 4 October 2024) Dr Gareth Payne Dr Ronit Pressler Dr Syed Shah Dr Rachel Thornton Dr Simon Freilich Dr Jiten Mistry Dr Tatyana Yermakova (Appointed 4 October 2024)
None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.
The trustees' report was approved by the Board of Trustees.
.............................. **Dr Gareth Payne** Trustee 5th October 2025 Dated: .........................
- 4 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **INDEPENDENT EXAMINER'S REPORT**
## **TO THE TRUSTEES OF THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
I report to the trustees on my examination of the financial statements of The British Society for Clinical Neurophysiology (the charitable company) for the year ended 30 June 2025.
## **Responsibilities and basis of report**
As the trustees of the charitable company (and also its directors for the purposes of company law), you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.
Having satisfied myself that the financial statements of the charitable company are not required to be audited under Part 16 of the Companies Act 2006 and are eligible for independent examination, I report in respect of my examination of the charitable company’s financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.
## **Independent examiner's statement**
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:
- 1 accounting records were not kept in respect of the charitable company as required by section 386 of the Companies Act 2006.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the Companies Act 2006 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.
## **Katherine Dee FCA**
Begbies Chartered Accountants 9 Bonhill Street London EC2A 4DJ
Dated: ....6/10/25........
- 5 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **STATEMENT OF FINANCIAL ACTIVITIES** _**FOR THE YEAR ENDED 30 JUNE 2025**_
|**Current financial year**
**Unrestricted**
**funds 2025**
**Restricted**
**funds**
**2025**
**Endowment**
**funds 2025**
**Notes**
**£**
**£**
**£**
Income from:
Donations and legacies
Charitable activities
Investments
**2**
**3**
**4**
25,905
47,135
5,441
-
-
1,309
-
-
-
**Total income**
78,481
1,309
-
Expenditure on:
Charitable activities
**5**
36,482
-
-
Net gains/(losses) on investments
**11**
1,196
-
879
**Net incoming resources before**
**transfers**
43,195
1,309
879
Gross transfers between funds
879
-
(879)
**Net movement in funds**
44,074
1,309
-
Fund balances at 1 July 2024
185,512
21,777
10,000
**Fund balances at 30 June 2025**
229,586
23,086
10,000|**Total**
**2025**
**£**
25,905
47,135
6,750
79,790
36,482
2,075
45,383
-
45,383
217,289
262,672|Total
2024
**£**
22,162
37,203
6,411
65,776
67,686
5,200
3,290
-
3,290
213,999
217,289|
|---|---|---|
The statement of financial activities includes all gains and losses recognised in the year.
The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.
- 6 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
|**Prior financial year**
**Unrestricted**
**funds 2024 £**
**Restricted**
**funds**
**2024**
**Endowment**
**funds 2024**
**Notes**
**£**
**£**
Income from:
Donations and legacies
Charitable activities
Investments
**2**
**3**
**4**
22,162
37,203
5,167
-
-
1,244
-
-
-
**Total income**
64,532
1,244
-
Expenditure on:
Charitable activities
**5**
67,199
487
-
Net gains/(losses) on investments
**11**
3,596
-
1,604
**Net incoming resources before transfers**
929
757
1,604
Gross transfers between funds
1,604
-
(1,604)
**Net movement in funds**
2,533
757
-
Fund balances at 1 July 2023
182,979
21,020
10,000
**Fund balances at 30 June 2024**
185,512
21,777
10,000|**Total**
**2024**
**£**
22,162
37,203
6,411
65,776
67,686
5,200
3,290
-
3,290
213,999
217,289|
|---|---|
The statement of financial activities includes all gains and losses recognised in the year.
The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.
- 7 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **SUMMARY INCOME AND EXPENDITURE ACCOUNT**
## _**FOR THE YEAR ENDED 30 JUNE 2025**_
|**All income funds**
**2025**
**£**
Gross income
Gains on investments
Transfer from endowment funds
79,790
1,196
879
Total income in the reporting period
81,865
Total expenditure from income funds
36,482
**Net income for the year**
45,383|**2024**
**£**
65,776
3,596
1,604
70,976
67,686
3,290|
|---|---|
- 8 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **BALANCE SHEET**
## _**AS AT 30 JUNE 2025**_
|**Notes**
**Fixed assets**
Investments
**13**
**Current assets**
Debtors
**14**
Cash at bank and in hand
**Creditors: amounts falling due within**
**one year**
**15**
**Net current assets**
**Net assets**
**The funds of the charitable company**
Endowment funds
Restricted income funds
Unrestricted funds
**17**
**18**|**2025**
**£**
5,382
169,605
174,987
(3,279)|**£**
90,964
171,708
262,672
10,000
23,086
229,586
262,672|**2024**
**£**
916
138,903
139,819
(11,419)|**£**
88,889
128,400
217,289
10,000
21,777
185,512
217,289|
|---|---|---|---|---|
For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
10th September 2025
The financial statements were approved by the trustees on .........................
.............................. .............................. Professor Mark Baker Dr Gareth Payne **Trustee Trustee**
Company registration number 493724 (England and Wales)
- 9 -
**THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 30 JUNE 2025**_
## **1 Accounting policies**
## **Charity information**
The British Society for Clinical Neurophysiology is a private company limited by guarantee incorporated in England and Wales. The registered office is 9 Bonhill Street, London, EC2A 4DJ.
All of the trustees are members of the company and guarantee to contribute £2 in the event of a winding up.
## **1.1 Accounting convention**
The financial statements have been prepared in accordance with the charitable company's governing document, the Companies Act 2006, FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable company is a Public Benefit Entity as defined by FRS 102.
The charitable company has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.
The financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
## **1.2 Going concern**
At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
## **1.3 Charitable funds**
## MSC Fund
The Medical Standing Committee fund was established from the residual reserves of the Association of British Clinical Neurophysiologists, which were donated during the year ended 30 June 2006. No travel expenses were reimbursed from this fund during the year.
## The Christine and Adrian Fowle Prize Fund
This prize fund, established by past president of the society Adrian Fowle and his wife Christine is intended to recognise excellence in the practice of clinical neurophysiology other than in science, and in particular in its human aspects. £5,000 (plus £1,250 of gift aid) was donated to the Society in 2020.
## Dr Last Memorial Fund
This expendable endowment fund was established by a generous donation from Dr Last's family and a contribution from the Society's reserves. Its purpose is to further the objectives of the Society, in particular in assisting younger members, by making grants to support foreign travel, enabling the recipient to visit laboratories where they may wish to learn new techniques or to plan or carry out joint research. It was not originally intended that funds should be used to facilitate attendance at conferences but it has been subsequently agreed that the fund may be used to finance bursaries. The fund originally comprised £10,000 of M & G Charifund units which yield an annual income and provides capital growth. During the year the investment generated investment income of £1,244. The committee will intend to distribute the annual income from the fund and may sell units to give additional finance provided that the market value of the capital invested in the fund does not fall below £10,000. It may make awards to one or more applicants or make no award if applicants are not considered suitable or if insufficient funds are available.
- 10 -
**THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
## **1 Accounting policies**
**(Continued)**
## **1.4 Incoming resources**
Incoming resources from charitable activities are recognised on an accruals basis. Investment income is received gross and accounted for on an accruals basis.
Cash donations are recognised on receipt. Membership fees are recorded as donations.
No provision has been made in these accounts for subscriptions unpaid at the end of the year. Subscriptions are recognised in full in the year in which they are received.
## **1.5 Resources expended**
Resources expended are recognised in the year in which they are incurred. Support costs are those costs incurred in support of expenditure on the objects of the charity. Governance costs are those incurred in connection with compliance with constitutional and statutory requirements. No support or governance cost are allocated to the category of awards and prizes as the general overhead time is immaterial.
## **1.6 Fixed asset investments**
Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.
## **1.7 Cash and cash equivalents**
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
## **1.8 Financial instruments**
The charitable company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the charitable company's balance sheet when the charitable company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
## _**Basic financial assets**_
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
- 11 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 30 JUNE 2025**_
## **1 Accounting policies**
**(Continued)**
## _**Basic financial liabilities**_
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
## _**Derecognition of financial liabilities**_
Financial liabilities are derecognised when the charitable company’s contractual obligations expire or are discharged or cancelled.
## **2 Donations and legacies**
|Membership fees|**2025**
**£**
25,905
25,905|2024
£
22,162
22,162|
|---|---|---|
- 12 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 30 JUNE 2025**_
## **3 Charitable activities**
|Delegate fee income
Exhibitor fee income
Analysis by fund
Unrestricted funds
**For the year ended 30 June 2024**
Unrestricted funds|**2025**
**£**
37,335
9,800
47,135
47,135|**2024**
**£**
17,003
20,200
37,203
37,203
37,203|
|---|---|---|
Income from charitable activities consists of income from three scientific meetings (2024: three), and two courses (2024: two).
## **4 Investments**
|**Unrestricted**
**funds**
**Restricted**
**funds**
**£**
**£**
Income From Listed Investments
Bank Interest
3,191
2,250
1,309
-
5,441
1,309
**For the year ended 30 June 2024**
5,167
1,244|**Total**
**2025**
**£**
4,500
2,250
6,750|**Total**
**2024**
**£**
4,167
2,244
6,411
6,411|
|---|---|---|
- 13 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 30 JUNE 2025**_
## **5 Charitable activities**
|**Scientific**
**Meetings**
**Grants and**
**Awards**
**£**
**£**
Meeting costs
10,656
-
Grant funding of activities (see note 6)
-
4,847
Share of support costs (see note 7)
Share of governance costs (see note 7)
17,811
3,168
-
-
31,635
4,847
Analysis by fund
Unrestricted funds
31,635
31,635
4,847
4,847
**For the year ended 30 June 2024**
Meeting costs
22,273
Analysis by fund
Unrestricted funds
Restricted funds
-
Grant funding of activities (see note 6)
-
15,819
Share of support costs (see note 7)
Share of governance costs (see note 7)
24,198
5,396
-
-
51,867
15,819
51,380
487
15,819
-
51,867
15,819|**Total**
**2025**
**£**
10,656
4,847
17,811
3,168
36,482
36,482
36,482|**Total**
**2024**
**£**
22,273
15,819
24,198
5,396
67,686
22,273
15,819
24,198
5,396
67,686
67,199
487
67,686|
|---|---|---|
## **6 Grants payable**
|Grants to individuals
**For the year ended 30 June 2024**
Grants and Awards|**2025**
**£**
4,847
4,847
13,860|**2024**
**£**
15,819
15,819|
|---|---|---|
- 14 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
## **6 Grants payable**
## **(Continued)**
## 2025
General grants paid by the charitable company, consisting of the Adrian Prize for £1,000, the Medical Student Essay Prize for £500, and 7 bursaries totalling £2,688 to reimburse trainees attending the joint BSCN & ISCN Spring Meeting in Dublin and one bursary for £500 to attend an ISIN training course. In addition one book bursary was awarded.
## 2024
General grants paid by the charitable company, consisting of the Adrian Prize for £1,000, the Medical Student Essay Prize for £500, and 11 bursaries of £500 each (totalling £5,500) to reimburse trainees attending the EEG Course in Cambridge. In addition 8 book bursaries were awarded.
## **7 Support costs**
|**Support Governance**
**costs costs**
**£**
**£**
Website
Clerical Assistance
Subscription - IFCN
Subscription - JNC
Subscription - AANEM
Bank charges
Sundry expenses
1,289
14,107
1,100
250
204
789
72
-
-
-
-
-
-
-
Examination fees
Legal and professional
Trustee meeting and dinner
-
-
-
3,133
35
-
17,811
3,168
Analysed between
Charitable activities
17,811
3,168|**2025**
**£**
1,289
14,107
1,100
250
204
789
72
3,133
35
-
20,979
20,979|2024
£
6,660
15,451
1,149
250
-
262
426
2,893
2,265
238
29,594
29,594|
|---|---|---|
## 2025
All support costs are attributable to scientific meetings.
2024
All support costs are attributable to scientific meetings.
Governance costs includes accountants' fees of £3,113 (2024- £2,893) for examination fees.
|**8**|**Net movement in funds**|**2025**|**2024**|
|---|---|---|---|
|||**£**|**£**|
||The net movement in funds is stated after charging/(crediting):|||
||Fees payable for the independent examination of the charity's financial|||
||statements|3,133|2,893|
- 15 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
## **9 Trustees**
None of the trustees (or any persons connected with them) received any remuneration or benefits from the charitable company during the year (2024: £0). No trustees claimed travel expenses (2024: 3 trustees: £913)
## **10 Employees**
The charitable company had no employees during the current or prior year.
There were no employees whose annual remuneration was more than £60,000.
## **11 Gains and losses on investments**
||**Unrestricted**|**Endowment**|**Total**|**Unrestricted**|**Endowment**|**Total**|
|---|---|---|---|---|---|---|
||**funds**|
**funds**||**funds**|
**funds**||
||**2025**|
**2025**|**2025**|**2024**|
**2024**|**2024**|
|Gains/(losses) arising on:|
**£**|
**£**|**£**|**£**|
**£**|**£**|
|Revaluation of|||||||
|investments|1,196|
879|2,075|3,596|
1,604|5,200|
## **12 Taxation**
The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.
## **13 Fixed asset investments**
|**Listed**
**investments**
**Unlisted**
**investments**
**£**
**£**
**Valuation**
At 1 July 2024
Additions
Valuation changes
Disposals
78,889
80,562
2,075
(80,562)
10,000
-
-
-
At 30 June 2025
80,964
10,000
**Carrying amount**
At 30 June 2025
80,964
10,000
At 30 June 2024
78,889
10,000|**Total**
**£**
88,889
80,562
2,075
(80,562)
90,964
90,964
88,889|
|---|---|
The original cost of the above investments totalled £90,562 (2024: £75,000). At the balance sheet date the listed investments held were M&G Charity Multi Asset Fund which is a unit trust. The unlisted investment is an NS&I Income Bond savings account.
- 16 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
|**14 Debtors**
**Amounts falling due within one year:**
Other debtors
Prepayments and accrued income
**15 Creditors: amounts falling due within one year**
**Notes**
Deferred income
Accruals
**16**|**2025**
**£**
3,419
1,963
5,382
**2025**
**£**
-
3,279
3,279|**2024**
**£**
-
916
916
**2024**
**£**
8,140
3,279
11,419|
|---|---|---|
## **16 Deferred income**
||**2025**|**2024**|
|---|---|---|
||**£**|**£**|
|Deferred scientific meeting delegate and|||
|exhibitor fees|-|8,140|
Deferred income consists of delegate and exhibitor fees received in advance of next year's scientific meetings.
## **17 Endowment funds**
Endowment funds represent assets which must be held permanently by the charitable company. Income arising on the endowment funds can be used in accordance with the objects of the charitable company and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.
||**At**|**1**|**July 2024**|**Transfers**|**Gains and**|**At 30 June**|
|---|---|---|---|---|---|---|
||||||**losses**|**2025**|
||||**£**|**£**|**£**|**£**|
|**Expendable endowments**|||||||
||||10,000|(879)|879|10,000|
- 17 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
|**17**|**Endowment funds**||||**(Continued)**|
|---|---|---|---|---|---|
||**Previous year:**|**At 1 July 2023**|**Transfers**|**Gains and**|**At 30 June**|
|||||**losses**|**2024**|
|||**£**|**£**|**£**|**£**|
||**Expendable endowments**|||||
|||10,000|(1,604)|1,604|10,000|
## **18 Restricted funds**
The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.
||**At**|**1 July 2024**|**Incoming**|**Resources**|**At 30 June**|**At 30 June**|
|---|---|---|---|---|---|---|
||||**resources**|**expended**||**2025**|
|||**£**|**£**|**£**||**£**|
|MSC Fund||12,006|-|-||12,006|
|Dr Last Memorial Fund||4,521|1,309|-||5,830|
|Christine and Adrian Fowle Prize Fund||5,250|-|-||5,250|
|||21,777|1,309|-||23,086|
|**Previous year:**|**At**|**1 July 2023**|**Incoming**|**Resources**|**At 30 June**||
||||**resources**|**expended**||**2024**|
|||**£**|**£**|**£**||**£**|
|MSC Fund||12,006|-|-||12,006|
|Dr Last Memorial Fund||3,277|1,244|-||4,521|
|Christine and Adrian Fowle Prize Fund||5,250|-|-||5,250|
|Visit Britain ECCN grant||487|-|(487)||-|
|||21,020|1,244|(487)||21,777|
## **19 Unrestricted funds**
The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.
||**At**|**1**|**July 2024**|**Incoming**|**Resources**|**Transfers**|**Gains and**|**At 30 June**|
|---|---|---|---|---|---|---|---|---|
|||||**resources**|**expended**||**losses**|**2025**|
||||**£**|**£**|**£**|**£**|**£**|**£**|
|General funds|||185,512|78,481|(36,482)|879|1,196|229,586|
- 18 -
## **THE BRITISH SOCIETY FOR CLINICAL NEUROPHYSIOLOGY**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 JUNE 2025**_
|**19**|**Unrestricted funds**|||||||**(Continued)**|
|---|---|---|---|---|---|---|---|---|
||**Previous year: At 1 July 2023**|||**Incoming**|**Resources**|**Transfers**|**Gains and**|**At 30 June**|
|||||**resources**|**expended**||**losses**|**2024**|
||||**£**|**£**|**£**|**£**|**£**|**£**|
||General funds|182,979||64,532|(67,199)|1,604|3,596|185,512|
|**20**|**Analysis of net assets between**||**funds**||||||
||||||**Unrestricted**|**Restricted**|**Endowment**|**Total**|
||||||**Fund**|**Funds**|**Fund**||
||||||**£**|**£**|**£**|**£**|
||Fund balances at 30 June 2025 are||||||||
||represented by:||||||||
||Investments||||80,964|-|10,000|90,964|
||Current assets/(liabilities)||||148,622|23,086|-|171,708|
||||||229,586|23,086|10,000|262,672|
||||||**£**|**£**|**£**|**£**|
||Fund balances at 30 June 2024 were||||||||
||represented by:||||||||
||Investments||||78,889|-|10,000|88,889|
||Current assets/(liabilities)||||106,623|21,777|-|128,400|
||||||185,512|21,777|10,000|217,289|
## **21 Related party transactions**
There were no disclosable related party transactions during the year (2024 - none), aside from the award of the £1,000 Adrian Prize to trustee Dr Charles Fry.
- 19 -